
Boulder Ventures is a specialty venture capital firm, investing in a niche geography, leveraging decades long relationships with proven entrepreneurs and evaluating early stage companies with deep technical and scientific expertise. We spend time and energy cultivating a network of serial entrepreneurs, because they are the source of Boulder Ventures investment ideas. Our serial entrepreneurs are subject matter experts. They consistently hatch market-leading ideas in information technology and life sciences that develop into market-leading companies in software, networking, data storage, drug discovery and tools, and technology enabled services. Our model is to be the first professional investor in our portfolio companies, and to reserve capital to participate in multiple investment rounds. We capture value and a deal flow advantage by focusing our investments in two underserved geographies: Colorado and the Mid-Atlantic. Boulder Ventures, with nearly 20 years of venture capital experience, continues to be a leading partner to serial entrepreneurs and a trusted advisor to our investors.
We're tracking Boulder Ventures's market expansion
How Boulder Ventures's international expansion compares to its competitors
Bars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
Boulder VenturesYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Boulder-based Ambrosia Biosciences secured $100 million in oversubscribed Series B funding to advance its oral small molecule GLP-1 through clinical trials, led by Blue Owl, Redmile, and Deep Track Capital.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Boulder Ventures's business, markets, and growth signals.

© 2026 Pubrio. All rights reserved.